Microbial dysbiosis and treatment‑related gastrointestinal adverse events in locoregionally advanced nasopharyngeal carcinoma: an exploratory study of the oral and gut microbiome
Gastrointestinal adverse events are frequent during treatment for locoregionally advanced nasopharyngeal carcinoma (LA‑NPC) and can impair nutritional status and treatment tolerance.
Gastrointestinal adverse events are frequent during treatment for locoregionally advanced nasopharyngeal carcinoma (LA‑NPC) and can impair nutritional status and treatment tolerance. Radiotherapy and chemotherapy may disrupt microbial communities, but whether oral and gut microbiota are associated with treatment‑related gastrointestinal adverse events remains unclear.
Associations between oral and gut microbiota and gastrointestinal toxicity during LA‑NPC treatment could inform biomarkers for risk stratification and lead to microbiome‑based interventions to improve patient outcomes.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Efficacy and Toxicity of Triweekly Versus Weekly Cisplatin in Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma